{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-035961","form_type":"8-K","ticker":"UNCY","cik":"0001766140","company_name":"Unicycive Therapeutics, Inc.","filed_at":"2026-03-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.108139+00:00","generated_at":"2026-05-15T08:25:00.153745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Unicycive Therapeutics FY2025 net loss $26.6M ($1.67/sh); OLC PDUFA date June 29, 2026","bullets":["Net loss attributable to common holders: $26.6M ($1.67/sh) vs $37.8M ($5.65/sh) in FY2024.","Cash, equivalents, securities $54.9M as of March 30, 2026; runway into 2027.","FDA accepted OLC NDA resubmission; PDUFA target action date June 29, 2026.","R&D expenses $9.1M (down from $20.0M); G&A $20.4M (up from $12.1M) due to commercial prep.","Commercial readiness for potential OLC launch in 3Q26 ongoing."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-035961","json":"https://secwatch.observer/filing/0001213900-26-035961.json","markdown":"https://secwatch.observer/filing/0001213900-26-035961.md","text":"https://secwatch.observer/filing/0001213900-26-035961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/0001213900-26-035961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/ea0283942-8k_unicycive.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:25:00.153745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dae72ea4b7ae0caac2c8b7a268303da3d675774c","claim":"Unicycive Therapeutics, Inc. reported the full year ended December 31, 2025 results: net income $26.6 million, EPS $1.67 per share of common stock.","evidence_excerpt":"Net loss attributable to common stockholders for the year ended December 31, 2025 was $26.6 million, or $1.67 per share of common stock, compared to a net loss attributable to common stockholders of $37.8 million, or $5.65 per share of common stock for the same period in 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1766140/000121390026035961/0001213900-26-035961-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Net income","value":"$26.6 million"},{"label":"EPS","value":"$1.67 per share of common stock"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}